{"paper_id":"37d0851b-72af-43c9-b01b-98ddad351de7","body_text":"Mini Review\n子宮内膜症におけるMAPKを介する炎症の解析と新たな治療戦略\n2004 年 24 巻 6 号 p. 629-633\n詳細\n抄録\nGiven the current theory of inflammatory changes being involved in the progression of endometriosis, MAPKs might be at play as pivotal intracellular signal transducers in endometriotic cells and thus have a pathophysiological role in the disease. In vitro study using endometriotic cell, all the MAPK inhibitors examined suppressed IL-1β-induced secretion of IL-6 and IL-8, and IL-1β-induced expression of COX-2 in endometriotic cells. Among MAPK inhibitors, p38MAPK inhibitor seemed to have the best potential to block inflammation. Then, the authors evaluated the effect of FR 167653, a p38MAPK inhibitor, on the development of endometriotic lesions and on the intraperitoneal inflammatory status using experimental model mice for endometriosis. FR 167653, a p38 MAPK inhibitor, caused a reduction in the growth of endometriotic lesions, coupled with the suppression of intraperitoneal inflammation. Thus, p38 MAPK inhibitors could have the therapeutic potential for endometriosis.\n© 2004 日本炎症･再生医学会","source_license":"CC0","license_restricted":false}